Drug Sponsors

Shire acquires Premacure

Wednesday, March 13, 2013 09:41 AM

Global specialty biopharmaceutical company Shire has acquired Premacure, a Swedish privately held biotechnology company developing a protein replacement therapy, currently in phase II development for the prevention of retinopathy of prematurity (ROP).

More... »

Galapagos and Roche conclude strategic alliance

Monday, March 11, 2013 10:38 AM

Galapagos, mid-size clinical stage biotechnology company, has agreed with Roche to end their alliance in fibrosis. Roche will make a payment of $975,000 to Galapagos for work completed in 2012, contributing to 2012 group revenues.

More... »

Biovest files for Ch. 11 bankruptcy protection

Friday, March 8, 2013 03:04 PM

Tampa, Fla.-based Biovest International has filed a petition for protection under Chapter 11 of the U.S. Bankruptcy Code and a Plan of Reorganization seeking to implement a restructuring of its balance sheet that would eliminate approximately $44 million in senior secured debt held by Laurus/Valens Funds and Corp Real, while also providing up to approximately $5.6 million in new operating funding.

More... »

CoCo Therapeutics created to develop new treatments for Alzheimer’s disease

Friday, March 8, 2013 12:08 PM

King’s College London, The Wellcome Trust and Advent Venture Partners have announced the formation of a new U.K. biotechnology company, CoCo Therapeutics, to progress the research of Professor Jonathan Corcoran into the development of new treatments for Alzheimer’s disease.

More... »

Merck names Roger Perlmutter president of Merck Research Laboratories

Thursday, March 7, 2013 01:37 PM

Merck has appointed Roger M. Perlmutter, M.D., Ph.D., executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role since 2003. To ensure a seamless transition, Dr. Perlmutter and Dr. Kim will work closely together for an initial period, after which Dr. Kim will remain with the company as an advisor until his retirement in August.

More... »

Mylan to acquire Agila to create global injectables platform

Thursday, February 28, 2013 03:19 PM

Pittsburgh-based Mylan has signed a definitive agreement to acquire Agila Specialties Private Limited, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab for $1.6 billion in cash.

More... »

Optimer board chairman McKinnell named CEO

Thursday, February 28, 2013 03:09 PM

The board of directors of Jersey City, N.J.-based Optimer Pharmaceuticals has appointed its chairman, Dr. Henry McKinnell, chief executive officer. McKinnell was Pfizer's CEO and chairman from 2001 to 2006 and was with Pfizer from 1971 until his retirement in 2007.

More... »

Roche launches process for accessing clinical trial data

Thursday, February 28, 2013 02:24 PM

Basel, Switzerland-based Roche is expanding access to its clinical trial data for third-party researchers. Roche will work with an independent body of recognized experts to evaluate and approve requests to access anonymized patient-level data.

More... »

Qualicaps to expand N.C. facility, create 123 jobs

Wednesday, February 27, 2013 12:23 PM

Qualicaps, a manufacturer of gelatin capsules and wholly owned subsidiary of Qualicaps Group, plans to expand its facility in Whitsett, N.C.

More... »

Intersect ENT raises $30M in Series D financing

Wednesday, February 27, 2013 10:58 AM

Intersect ENT, a Menlo Park, Calif.-based innovator in treatment solutions for ear, nose and throat clinicians and their patients, has completed the initial closing of a $30 million Series D round of funding. The financing will be used to continue the rapid commercial expansion in the U.S. for the company's PROPEL and PROPEL mini sinus implants and to fund clinical studies of the company's latest product, an office-based treatment for chronic sinusitis sufferers.

More... »